QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Information source: Bayer
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Multiple Sclerosis,; Relapsing-Remitting
Intervention: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
This study is to describe the quality of life of Korean patients with early
relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon
with several validated questionnaires.
Clinical Details
Official title: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Quality of life evaluated by several validated questionnaire
Secondary outcome: Information about safety of Betaferon in routine clinical use
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis
according to Poser or McDonald criteria, starting Betaferon treatment, including
patients switching from other DMDs
- Patients who signed informed consent form
Exclusion Criteria:
- Age lower than 18
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Korea, Republic of
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. Click here to find results for studies related to marketed products.
Starting date: January 2011
Last updated: August 25, 2010
|
